Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline based therapy

Clinical Lymphoma and Myeloma

Volumn 8, Issue 5, 2008, Pages 294-299

  Offidani, Massimo ^a   Corvatta, Laura ^b   Polloni, Claudia ^a   Piersantelli, Maria Novella ^a   Galieni, Piero ^c   Visani, Giuseppe ^d   Alesiani, Francesco ^e   Catarini, Massimo ^f   Brunori, Marino ^g   Burattini, Maurizio ^h   Centurioni, Riccardo ⁱ   Ferranti, Mario ^j   Giuliodori, Luciano ^k   Candela, Marco ^b   Mele, Anna ^l   Marconi, Monica ^g   Leoni, Pietro ^a  

^a OSPEDALI RIUNITI   (Italy)

^b Divisione Medicina Fabriano   (Italy)

^c Divisione Ematologia Ascoli Piceno   (Italy)

^d Divisione Ematologia Pesaro   (Italy)

^e Unità di Oncoematologia San Severino Marche   (Italy)

^f Divisione Medicina Macerata   (Italy)

^g Divisione Medicina Fano   (Italy)

^h Divisione Medicina Jesi   (Italy)

ⁱ Divisione Medicina Civitanova Marche   (Italy)

^j Divisione Medicina Tolentino   (Italy)

^k Servizio di Oncologia Fabriano   (Italy)

^l Ospedali Riuniti Ancona   (Italy)

more..

Author keywords

Gene expression profiling; Pegylated liposomal doxorubicin; Predictive factors

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; IMMUNOGLOBULIN A; SERUM ALBUMIN; THALIDOMIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CYTOGENETICS; DISEASE SEVERITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PLASMA CELL; PROGNOSIS; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT RESPONSE; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 58149340107     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.041     Document Type: Article

References (31)

1. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21-33.
2. 2-microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80:733-7.
3. Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 2003; 81:3382-7.
4. Bataille R, Durie BG, Grenier J, et al. Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol 1986; 4:80-7.
5. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97:1566-71.
6. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res 2002; 62:715-20.
7. Zhan F, Huang Y, Colla S, Stewart JP, et al. The molecular classification of multiple myeloma. Blood 2006; 108:2020-8.
8. Greipp PR, San Miguel J, Durie GM, et al. International Staging System for multiple myeloma. J Clin Oncol 2005; 23:3412-20.
9. Kumar SK, Rajkumar SV, Dispensieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-20.
10. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21:151-7.
11. Anagnostopoulos A, Goka D, Hamilos G, et al. Treatment of relapsed/ refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. Leuk Lymphoma 2004; 45:2275-9.
12. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic- cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021-30.
13. Shaughnessy JD, Haessler J, Zeldis J et al. An update on the role of thalidomide (Thal) in total therapy 2 (TT2) for newly diagnosed patients with multiple myeloma (MM): analysis of subgroups defined by standard prognostic factors a (SPF) and gene expression profiling (GEP) derived subgroups. Blood 2006; 108:968a (Abstract 3389).
14. Zamagni E, Testoni N, Terragna C, et al. Incorporation of thalidomide into up-front double autologous stem-cell transplantation (ASCT) for multiple myeloma improves the outcome in comparison with double ASCT without thalidomide. Analysis of base factors predictive of outcome. Blood 2007; 110:138a (Abstract 447).
15. 2-microglobulin, predicts outcome in myeloma patients who received thalidomide as salvage therapy. Cancer 2007; 110:824-9.
16. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108:2159-64.
17. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108:3289-94.
18. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21:529-34.
19. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102:69-77.
20. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98:492-4.
21. Hus I, Dmoszynska A, Manko J, et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br J Cancer 2004; 91:1873-9.
22. Herrmann JL, Blanchard H, Brunengo P, et al. TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. Infection 1994; 22:309-15.
23. Castell JV, Gómez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute phase protein synthesis by interleukin-6. Hepatology 1990; 12:1179-86.
24. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332:83-5.
25. Klein B, Zhang XG, Jourdan M, et al. A paracrine but not autocrine regulation of myeloma-cell growth and differentiation by interleukin 6. Blood 1989; 73:517-26.
26. Zhang XG, Klein B, Bataille R. Interleukin 6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74:11-3.
27. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97:2440-52.
28. Bruno B, Giaccone L, Rotta M, et al. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 2005; 19:1729-38.
29. Van de Broek I, Leleu X, Shots R, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 2006; 91:200-6.
30. Yi Q, Yang J, Wezeman M, et al. C-reactive protein protects myeloma cells from apoptosis via activating itam-containing FcgRII. Haematologica 2007; 92(suppl 2):PO-210, 3.
31. Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106:2977-81.